Top

Open Access 29-04-2024 | Acute Myeloid Leukemia | Original Research Article

ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study

Authors: Michael Maris, Gilles Salles, Won Seog Kim, Tae Min Kim, Roger M. Lyons, Martha Arellano, Reem Karmali, Gary Schiller, Elizabeth Cull, Camille N. Abboud, Connie Batlevi, Ioannis Kagiampakis, Marlon C. Rebelatto, Young Lee, Lyndon C. Kirby, Fujun Wang, John Bothos, Danielle M. Townsley, Amir T. Fathi, Vincent Ribrag

Published in: Targeted Oncology

Abstract

Background

MEDI7247 is a first-in-class antibody-drug conjugate (ADC) consisting of an anti-sodium-dependent alanine-serine-cysteine transporter 2 antibody-conjugated to a pyrrolobenzodiazepine dimer.

Objective

This first-in-human phase 1 trial evaluated MEDI7247 in patients with hematological malignancies.

Patients and methods

Adults with acute myeloid leukemia (AML), multiple myeloma (MM), or diffuse large B-cell lymphoma (DLBCL) relapsed or refractory (R/R) to standard therapies, or for whom no standard therapy exists, were eligible. Primary endpoints were safety and determination of the maximum tolerated dose (MTD). Secondary endpoints included assessments of antitumor activity, pharmacokinetics (PK), and immunogenicity.

Results

As of 26 March 2020, 67 patients were treated (AML: n = 27; MM: n = 18; DLBCL: n = 22). The most common MEDI7247-related adverse events (AEs) were thrombocytopenia (41.8%), neutropenia (35.8%), and anemia (28.4%). The most common treatment-related grade 3/4 AEs were thrombocytopenia (38.8%), neutropenia (34.3%), and anemia (22.4%). Anticancer activity (number of responders/total patients evaluated) was observed in 11/67 (16.4%) patients. No correlation was observed between ASCT2 expression and clinical response. Between-patient variability of systemic exposure of MEDI7247 ADC and total antibody were high (AUC_inf geometric CV%: 62.3–134.2, and 74.8–126.1, respectively). SG3199 (PBD dimer) plasma concentrations were below the limit of quantification for all patients after Study Day 8. Anti-drug antibody (ADA) prevalence was 7.7%, ADA incidence was 1.9%, and persistent-positive ADA was 5.8%.

Conclusions

Thrombocytopenia and neutropenia limited repeat dosing. Although limited clinical activity was detected, the dose-escalation phase was stopped early without establishing an MTD.

The study was registered with ClinicalTrials.gov (NCT03106428).

Available only for authorised users

Scalise M, Pochini L, Console L, Losso MA, Indiveri C. The Human SLC1A5 (ASCT2) amino acid transporter: from function to structure and role in cell biology. Front Cell Dev Biol. 2018;6:96. https://doi.org/10.3389/fcell.2018.00096.CrossRefPubMedPubMedCentral

Liu Y, Zhao T, Li Z, Wang L, Yuan S, Sun L. The role of ASCT2 in cancer: a review. Eur J Pharmacol. 2018;837:81–7. https://doi.org/10.1016/j.ejphar.2018.07.007.CrossRefPubMed

Hassanein M, Hoeksema MD, Shiota M, Qian J, Harris BK, Chen H, et al. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res. 2013;19(3):560–70. https://doi.org/10.1158/1078-0432.CCR-12-2334.CrossRefPubMed

Nikkuni O, Kaira K, Toyoda M, Shino M, Sakakura K, Takahashi K, et al. Expression of amino acid transporters (LAT1 and ASCT2) in patients with stage III/IV laryngeal squamous cell carcinoma. Pathol Oncol Res. 2015;21(4):1175–81. https://doi.org/10.1007/s12253-015-9954-3.CrossRefPubMed

Kaira K, Sunose Y, Arakawa K, Sunaga N, Shimizu K, Tominaga H, et al. Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma. Histopathology. 2015;66(2):234–43. https://doi.org/10.1111/his.12464.CrossRefPubMed

Wang Q, Hardie RA, Hoy AJ, van Geldermalsen M, Gao D, Fazli L, et al. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J Pathol. 2015;236(3):278–89. https://doi.org/10.1002/path.4518.CrossRefPubMedPubMedCentral

van Geldermalsen M, Wang Q, Nagarajah R, Marshall AD, Thoeng A, Gao D, et al. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene. 2016;35(24):3201–8. https://doi.org/10.1038/onc.2015.381.CrossRefPubMed

Shimizu K, Kaira K, Tomizawa Y, Sunaga N, Kawashima O, Oriuchi N, et al. ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer. Br J Cancer. 2014;110(8):2030–9. https://doi.org/10.1038/bjc.2014.88.CrossRefPubMedPubMedCentral

Monks NR, Schifferli KP, Tammali R, Borrok MJ, Coats SR, Herbst R, et al. MEDI7247, a novel pyrrolobenzodiazepine ADC targeting ASCT2 with potent in vivo activity across a spectrum of hematological malignancies. Cancer Res. 2018;78(13_Supplement):LB-295. https://doi.org/10.1158/1538-7445.AM2018-LB-295.CrossRef

10.

Pore N, Schifferli KP, Monks NR, Tammali R, Borrok M, Hurt E, et al. Discovery and development of MEDI7247, a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2, for treating hematological cancers. Blood. 2018;132(Supplement 1):4071. https://doi.org/10.1182/blood-2018-99-119836.CrossRef

11.

Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–8. https://doi.org/10.1182/blood-2017-03-769620.CrossRefPubMedPubMedCentral

12.

Luppi M, Fabbiano F, Visani G, Martinelli G, Venditti A. Novel agents for acute myeloid leukemia. Cancers (Basel). 2018. https://doi.org/10.3390/cancers10110429.CrossRefPubMed

13.

Ndaru E, Garibsingh RA, Shi Y, Wallace E, Zakrepine P, Wang J, et al. Novel alanine serine cysteine transporter 2 (ASCT2) inhibitors based on sulfonamide and sulfonic acid ester scaffolds. J Gen Physiol. 2019;151(3):357–68. https://doi.org/10.1085/jgp.201812276.CrossRefPubMedPubMedCentral

14.

Mecklenburg L. A brief introduction to antibody-drug conjugates for toxicologic pathologists. Toxicol Pathol. 2018;46(7):746–52. https://doi.org/10.1177/0192623318803059.CrossRefPubMed

15.

Hartley JA, Flynn MJ, Bingham JP, Corbett S, Reinert H, Tiberghien A, et al. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Sci Rep. 2018;8(1):10479. https://doi.org/10.1038/s41598-018-28533-4.CrossRefPubMedPubMedCentral

16.

Nejadmoghaddam MR, Minai-Tehrani A, Ghahremanzadeh R, Mahmoudi M, Dinarvand R, Zarnani AH. Antibody-drug conjugates: possibilities and challenges. Avicenna J Med Biotechnol. 2019;11(1):3–23.PubMedPubMedCentral

17.

Ji Y, Liu P, Li Y, Bekele BN. A modified toxicity probability interval method for dose-finding trials. Clin Trials. 2010;7(6):653–63. https://doi.org/10.1177/1740774510382799.CrossRefPubMedPubMedCentral

18.

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47. https://doi.org/10.1182/blood-2016-08-733196.CrossRefPubMedPubMedCentral

19.

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46. https://doi.org/10.1016/S1470-2045(16)30206-6.CrossRefPubMed

20.

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68. https://doi.org/10.1200/JCO.2013.54.8800.CrossRefPubMedPubMedCentral

21.

Papaemmanuil E, Dohner H, Campbell PJ. Genomic classification in acute myeloid leukemia. N Engl J Med. 2016;375(9):900–1. https://doi.org/10.1056/NEJMc1608739.CrossRefPubMed

22.

Rothenberg-Thurley M, Amler S, Goerlich D, Kohnke T, Konstandin NP, Schneider S, et al. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia. 2018;32(7):1598–608. https://doi.org/10.1038/s41375-018-0034-z.CrossRefPubMedPubMedCentral

23.

Yilmaz M, Richard S, Jabbour E. The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. Ther Adv Hematol. 2015;6(5):253–61. https://doi.org/10.1177/2040620715596715.CrossRefPubMedPubMedCentral

24.

Wynne J, Wright D, Stock W. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019;3(1):96–104. https://doi.org/10.1182/bloodadvances.2018026211.CrossRefPubMedPubMedCentral

25.

Yu B, Liu D. Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia. Biomark Res. 2019;7:24. https://doi.org/10.1186/s40364-019-0175-x.CrossRefPubMedPubMedCentral

26.

Phillips T, Barr PM, Park SI, Kolibaba K, Caimi PF, Chhabra S, et al. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. Invest New Drugs. 2019;37(2):297–306. https://doi.org/10.1007/s10637-018-0655-0.CrossRefPubMed

27.

Janjigian YY, Lee W, Kris MG, Miller VA, Krug LM, Azzoli CG, et al. A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemother Pharmacol. 2010;65(5):833–8. https://doi.org/10.1007/s00280-009-1088-4.CrossRefPubMed

28.

Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II TRINITY study. Clin Cancer Res. 2019;25(23):6958–66. https://doi.org/10.1158/1078-0432.CCR-19-1133.CrossRefPubMedPubMedCentral

29.

McDonald GB, Freston JW, Boyer JL, DeLeve LD. Liver complications following treatment of hematologic malignancy with anti-CD22-calicheamicin (inotuzumab ozogamicin). Hepatology. 2019;69(2):831–44. https://doi.org/10.1002/hep.30222.CrossRefPubMed

30.

Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019;394(10200):793–804. https://doi.org/10.1016/S0140-6736(19)31774-X.CrossRefPubMed

31.

Zhao H, Gulesserian S, Ganesan SK, Ou J, Morrison K, Zeng Z, et al. Inhibition of megakaryocyte differentiation by antibody-drug conjugates (ADCs) is mediated by macropinocytosis: implications for ADC-induced thrombocytopenia. Mol Cancer Ther. 2017;16(9):1877–86. https://doi.org/10.1158/1535-7163.MCT-16-0710.CrossRefPubMed

32.

Ramesh R, Marrogi AJ, Munshi A, Abboud CN, Freeman SM. In vivo analysis of the “bystander effect”: a cytokine cascade. Exp Hematol. 1996;24(7):829–38.PubMed

33.

Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, et al. The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53(21):5274–83.PubMed

34.

Cancer Cell Line Encyclopedia. 2021. https://portals.broadinstitute.org/ccle.

35.

Lagunas-Rangel FA, Chavez-Valencia V. FLT3-ITD and its current role in acute myeloid leukaemia. Med Oncol. 2017;34(6):114. https://doi.org/10.1007/s12032-017-0970-x.CrossRefPubMed

Title: ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study
Authors: Michael Maris
Gilles Salles
Won Seog Kim
Tae Min Kim
Roger M. Lyons
Martha Arellano
Reem Karmali
Gary Schiller
Elizabeth Cull
Camille N. Abboud
Connie Batlevi
Ioannis Kagiampakis
Marlon C. Rebelatto
Young Lee
Lyndon C. Kirby
Fujun Wang
John Bothos
Danielle M. Townsley
Amir T. Fathi
Vincent Ribrag
Publication date: 29-04-2024
Publisher: Springer International Publishing
Keywords: Acute Myeloid Leukemia
Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Pharmacokinetics
Neutropenia
Thrombocytopenia
Published in: Targeted Oncology
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-024-01054-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine